Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumiliximab + FCR vs FCR in Untreated CLL
NCT00801060Phase 2Terminated
- Sponsor
- Biogen
- Start
- Feb 2008
- Primary completion
- Jun 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of lumiliximab in chronic lymphocytic leukemia (CLL), sponsored by Biogen. Started Feb 2008; status: terminated.
02
Drugs
lumiliximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00801060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00801060.